BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 22495167)

  • 1. Clinical impact of BNP and other emerging biomarkers in heart failure evaluation and management.
    Palazzuoli A; Caputo M; Calabrò A; Nuti R
    Minerva Cardioangiol; 2012 Apr; 60(2):183-94. PubMed ID: 22495167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarkers in heart failure management.
    Isaac DL
    Curr Opin Cardiol; 2008 Mar; 23(2):127-33. PubMed ID: 18303525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Biomarkers in heart failure: BNP and NT-proBNP].
    Ho CC; Liu CC
    Hu Li Za Zhi; 2009 Oct; 56(5):16-22. PubMed ID: 19760573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BNP in the diagnosis and risk stratification of heart failure.
    Moe GW
    Heart Fail Monit; 2005; 4(4):116-22. PubMed ID: 16234898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B-type natriuretic peptide in heart failure.
    Moe GW
    Curr Opin Cardiol; 2006 May; 21(3):208-14. PubMed ID: 16601459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining natriuretic peptides and necrosis markers in determining prognosis in heart failure.
    Fonarow GC; Horwich TB
    Rev Cardiovasc Med; 2003; 4 Suppl 4():S20-8. PubMed ID: 14564225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic utility of B-type natriuretic peptide assessment in stable low-risk outpatients with nonischemic cardiomyopathy after decompensated heart failure.
    Nishii M; Inomata T; Takehana H; Naruke T; Yanagisawa T; Moriguchi M; Takeda S; Izumi T
    J Am Coll Cardiol; 2008 Jun; 51(24):2329-35. PubMed ID: 18549918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in heart failure: natriuretic peptide testing.
    Rehman SU; Januzzi JL
    Panminerva Med; 2008 Jun; 50(2):139-51. PubMed ID: 18607337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurohormonal and inflammatory markers as predictors of short-term outcome in patients with heart failure and cardiac resynchronization therapy.
    Glick A; Michowitz Y; Keren G; George J
    Isr Med Assoc J; 2006 Jun; 8(6):391-5. PubMed ID: 16833167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of b-type natriuretic peptide in heart failure management.
    Newton PJ; Betihavas V; Macdonald P
    Aust Crit Care; 2009 Aug; 22(3):117-23. PubMed ID: 19589695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amino-terminal pro-B-type natriuretic peptide testing for the diagnosis or exclusion of heart failure in patients with acute symptoms.
    Januzzi JL; Chen-Tournoux AA; Moe G
    Am J Cardiol; 2008 Feb; 101(3A):29-38. PubMed ID: 18243855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of natriuretic peptide testing in guiding chronic heart failure management: review of available data and recommendations for use.
    Januzzi JL
    Arch Cardiovasc Dis; 2012 Jan; 105(1):40-50. PubMed ID: 22369917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natriuretic peptide-guided management of acutely destabilized heart failure: rationale and treatment algorithm.
    Bhardwaj A; Januzzi JL
    Crit Pathw Cardiol; 2009 Dec; 8(4):146-50. PubMed ID: 19952548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction in BNP levels with treatment of decompensated heart failure and future clinical events.
    Dhaliwal AS; Deswal A; Pritchett A; Aguilar D; Kar B; Souchek J; Bozkurt B
    J Card Fail; 2009 May; 15(4):293-9. PubMed ID: 19398076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brain natriuretic peptide-guided therapy in the inpatient management of decompensated heart failure.
    Saremi A; Gopal D; Maisel AS
    Expert Rev Cardiovasc Ther; 2012 Feb; 10(2):191-203. PubMed ID: 22292875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognosis of stage A or B heart failure patients with elevated B-type natriuretic peptide levels.
    Daniels LB; Clopton P; Jiang K; Greenberg B; Maisel AS
    J Card Fail; 2010 Feb; 16(2):93-8. PubMed ID: 20142019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimization of the use of B-type natriuretic peptide levels for risk stratification at discharge in elderly patients with decompensated heart failure.
    Cournot M; Mourre F; Castel F; Ferrières J; Destrac S
    Am Heart J; 2008 Jun; 155(6):986-91. PubMed ID: 18513508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B-type natriuretic Peptide-guided treatment for predicting outcome in patients hospitalized in sub-intensive care unit with acute heart failure.
    Valle R; Aspromonte N; Giovinazzo P; Carbonieri E; Chiatto M; di Tano G; Feola M; Milli M; Fontebasso A; Barro S; Bardellotto S; Milani L
    J Card Fail; 2008 Apr; 14(3):219-24. PubMed ID: 18381185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-terminal proBNP: a novel biomarker for the diagnosis, risk stratification and management of congestive heart failure.
    O'Donoghue M; Januzzi JL
    Expert Rev Cardiovasc Ther; 2005 May; 3(3):487-96. PubMed ID: 15889976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of serial increases in amino-terminal pro-B-type natriuretic peptide levels to indicate the need for mechanical circulatory support in children with acute decompensated heart failure.
    Wong DT; George K; Wilson J; Manlhiot C; McCrindle BW; Adeli K; Kantor PF
    Am J Cardiol; 2011 Feb; 107(4):573-8. PubMed ID: 21295174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.